Regulus Restructures Collaboration With Sanofi
November 06 2018 - 7:53AM
Dow Jones News
By Michael Dabaie
Regulus Therapeutics Inc. (RGLS) said Tuesday it restructured
its collaboration and license agreement with Sanofi (SNY).
Regulus granted Sanofi a world-wide exclusive license to develop
and commercialize its investigational drug, targeting miR-21 for
all indications including Alport syndrome. Sanofi will assume all
future costs and development activities for advancement of RG-012,
which is currently in Phase 2 for Alport syndrome.
Regulus is eligible to receive approximately $7 million in
upfront and material transfer payments and up to $40 million in
development milestone payments. In addition, Sanofi will reimburse
Regulus for certain out-of-pocket transition activities and assume
Regulus' upstream license royalty obligations.
Shares of Regulus were up 24% at $2.33 premarket.
Alport syndrome is an inherited form of kidney disease. It
represents a high unmet medical need with no approved therapy,
Regulus said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 06, 2018 08:38 ET (13:38 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024